SPRO Logo

SPRO Stock Forecast: Spero Therapeutics Inc. Price Predictions for 2026

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$2.91

+0.01 (0.34%)

SPRO Stock Forecast 2025-2026

$2.91
Current Price
$162.70M
Market Cap
3 Ratings
Buy 1
Hold 2
Sell 0
Wall St Analyst Ratings

Distance to SPRO Price Targets

+71.8%
To High Target of $5.00
+71.8%
To Median Target of $5.00
+71.8%
To Low Target of $5.00

SPRO Price Momentum

+0.3%
1 Week Change
+16.4%
1 Month Change
+129.1%
1 Year Change
+182.5%
Year-to-Date Change
-5.8%
From 52W High of $3.09
+476.2%
From 52W Low of $0.51
๐Ÿ“Š TOP ANALYST CALLS

Did SPRO Make This Month's Elite Buy List?

We don't follow just any analyst โ€” only the top 3% with a proven track record make our cut. See if Spero is one of their latest high-conviction picks.

Join 5,000+ investors getting our data-driven analysis. Unsubscribe anytime.

Latest SPRO Stock Price Targets & Analyst Predictions

Based on our analysis of 6 Wall Street analysts, SPRO has a neutral consensus with a median price target of $5.00 (ranging from $5.00 to $5.00). Currently trading at $2.91, the median forecast implies a 71.8% upside. This outlook is supported by 1 Buy, 2 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 71.8% upside. Conversely, the most conservative target is provided by Raghuram Selvaraju at HC Wainwright & Co., suggesting a 71.8% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

SPRO Analyst Ratings

1
Buy
2
Hold
0
Sell

SPRO Price Target Range

Low
$5.00
Average
$5.00
High
$5.00
Current: $2.91

Latest SPRO Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for SPRO.

Date Firm Analyst Rating Change Price Target
Jan 30, 2025 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $5.00
Dec 20, 2024 Evercore ISI Group Josh Schimmer In-Line Downgrade $5.00
Dec 2, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $5.00
Nov 18, 2024 TD Cowen Ritu Baral Hold Downgrade $0.00
Nov 15, 2024 Cantor Fitzgerald Louise Chen Overweight Reiterates $0.00
Nov 4, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Maintains $5.00
Oct 3, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $7.00
Aug 6, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $7.00
Aug 6, 2024 TD Cowen Ritu Baral Buy Upgrade $0.00
Aug 6, 2024 Cantor Fitzgerald Louise Chen Overweight Reiterates $0.00
May 16, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $7.00
Apr 4, 2024 Cantor Fitzgerald Louise Chen Overweight Reiterates $0.00
Mar 18, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $7.00
Nov 14, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $7.00
Sep 5, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $7.00
Aug 14, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Maintains $7.00
Aug 1, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $6.00
Jul 20, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $6.00
Apr 10, 2023 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $6.00
Sep 26, 2022 HC Wainwright & Co. Raghuram Selvaraju Buy Maintains $6.00

Spero Therapeutics Inc. (SPRO) Competitors

The following stocks are similar to Spero based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Spero Therapeutics Inc. (SPRO) Financial Data

Spero Therapeutics Inc. has a market capitalization of $162.70M with a P/E ratio of 10.8x. The company generates $44.58M in trailing twelve-month revenue with a -156.5% profit margin.

Revenue growth is -36.6% quarter-over-quarter, while maintaining an operating margin of -247.8% and return on equity of -107.3%.

Valuation Metrics

Market Cap $162.70M
Enterprise Value $117.21M
P/E Ratio 10.8x
PEG Ratio -2.6x
Price/Sales 3.6x

Growth & Margins

Revenue Growth (YoY) -36.6%
Gross Margin N/A
Operating Margin -247.8%
Net Margin -156.5%
EPS Growth +21.6%

Financial Health

Cash/Price Ratio +30.0%
Current Ratio 2.6x
Debt/Equity 11.7x
ROE -107.3%
ROA -37.2%
๐Ÿ’ก SKIP THE NOISE

97% of Analyst Ratings Go Nowhere

We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ€” tracked and updated every Monday and Thursday.

Join 5,000+ investors getting our data-driven analysis. Unsubscribe anytime.

Spero Therapeutics Inc. logo

Spero Therapeutics Inc. (SPRO) Business Model

About Spero Therapeutics Inc.

What They Do

Develops treatments for antibiotic-resistant infections.

Business Model

Spero Therapeutics generates revenue through the development and commercialization of novel antibiotic therapies aimed at treating multi-drug resistant infections. The company focuses on both oral and intravenous treatment options, leveraging cutting-edge research to create effective alternatives in healthcare.

Additional Information

Headquartered in Cambridge, Massachusetts, Spero Therapeutics addresses the significant public health challenge posed by antibiotic resistance, which is increasingly concerning for global health systems. The companyโ€™s innovative pipeline is crucial for hospitals and healthcare environments where traditional antibiotics are often ineffective.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

32

CEO

Ms. Esther P. Rajavelu

Country

United States

IPO Year

2017

Spero Therapeutics Inc. (SPRO) Latest News & Analysis

Featured Analysis
Powered by Zacks Investment Research

AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer

AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.

Jul 04, 2025 By Zacks Equity Research Analyst Blog

RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance

FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.

Jul 01, 2025 By Zacks Equity Research Analyst Blog

ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B

AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.

Jul 01, 2025 By Zacks Equity Research Analyst Blog

Latest News

SPRO stock latest news image
Quick Summary

Tebipenem is anticipated to receive approval by mid-2026, with GSK handling commercialization. This could lead to $175 million in milestone payments for Spero over the next year.

Why It Matters

Spero's potential $175 million milestone payments and GSK's commercialization support reduce financial risk, enhancing Spero's valuation and attractiveness to investors.

Source: Seeking Alpha
Market Sentiment: Positive
SPRO stock latest news image
Quick Summary

SPRO shares rise following positive phase III results for a GSK-partnered oral drug, advancing towards FDA filing and potential changes in cUTI treatment options.

Why It Matters

SPRO's share surge signals strong market confidence following successful drug trials, potentially enhancing revenue and market position in cUTI treatment options.

Source: Zacks Investment Research
Market Sentiment: Positive
SPRO stock latest news image
Quick Summary

GSK and Spero Therapeutics announced that the phase 3 PIVOT-PO trial of tebipenem HBr for complicated urinary tract infections will end early due to efficacy results.

Why It Matters

The early efficacy stop of the PIVOT-PO trial for tebipenem HBr suggests strong potential for GSK and Spero, likely boosting their stock prices and market confidence.

Source: Benzinga
Market Sentiment: Positive
SPRO stock latest news image
Quick Summary

Spero Therapeutics and GSK's tebipenem HBr has met primary endpoints in a Phase 3 trial for treating complicated urinary tract infections, with an FDA filing planned for 2H 2025.

Why It Matters

Approval of tebipenem HBr could disrupt the cUTI treatment market, addressing a significant healthcare cost burden and enhancing Spero Therapeutics' growth potential and stock value.

Source: GlobeNewsWire
Market Sentiment: Neutral
SPRO stock latest news image
Quick Summary

Spero Therapeutics, Inc. (Nasdaq: SPRO) reported its Q1 2025 financial results and provided a business update as it continues to develop treatments for rare diseases and MDR infections.

Why It Matters

Spero Therapeutics' quarterly results and business update may influence stock performance and investor sentiment, especially regarding its pipeline for rare diseases and MDR infections.

Source: GlobeNewsWire
Market Sentiment: Neutral
SPRO stock latest news image
Quick Summary

Spero Therapeutics (SPRO) reported a quarterly loss of $0.25 per share, outperforming the Zacks Consensus Estimate of $0.55. This compares to a loss of $0.24 per share last year.

Why It Matters

Spero Therapeutics' smaller-than-expected loss signals improved performance, potentially boosting investor confidence and stock value.

Source: Zacks Investment Research
Market Sentiment: Negative

Frequently Asked Questions About SPRO Stock

What is Spero Therapeutics Inc.'s (SPRO) stock forecast for 2026?

Based on our analysis of 6 Wall Street analysts, Spero Therapeutics Inc. (SPRO) has a median price target of $5.00. The highest price target is $5.00 and the lowest is $5.00.

Is SPRO stock a good investment in 2026?

According to current analyst ratings, SPRO has 1 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.91. Always conduct your own research and consider your investment goals before making investment decisions.

What is the long-term price prediction for SPRO stock?

Wall Street analysts predict SPRO stock could reach $5.00 in the next 12 months. This represents a 71.8% increase from the current price of $2.91. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Spero Therapeutics Inc.'s business model?

Spero Therapeutics generates revenue through the development and commercialization of novel antibiotic therapies aimed at treating multi-drug resistant infections. The company focuses on both oral and intravenous treatment options, leveraging cutting-edge research to create effective alternatives in healthcare.

What is the highest forecasted price for SPRO Spero Therapeutics Inc.?

The highest price target for SPRO is $5.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 71.8% increase from the current price of $2.91.

What is the lowest forecasted price for SPRO Spero Therapeutics Inc.?

The lowest price target for SPRO is $5.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 71.8% increase from the current price of $2.91.

What is the overall SPRO consensus from analysts for Spero Therapeutics Inc.?

The overall analyst consensus for SPRO is neutral. Out of 6 Wall Street analysts, 1 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $5.00.

How accurate are SPRO stock price projections?

Stock price projections, including those for Spero Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.

Important Disclaimer

The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Last updated: July 7, 2025 11:06 PM UTC
Serious About Growing Your Portfolio?

We highlight 2 high-upside stocks each month – no fluff.

Missed GME or NVDA? Donโ€™t Miss the Next One.โ€‹

Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ€” for free.